Akihiro Takano

Stockholm, AB 17177, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications

[18F]MNI-1054, a novel PET ligand for lysine-specific histone demethylase 1 A (LSD1): first-in human validation and enzyme occupancy of the LSD1 inhibitor TAK-418.

[18F]MNI-1054, a novel PET ligand for lysine-specific histone demethylase 1 A (LSD1): first-in human validation and enzyme occupancy of the LSD1 inhibitor TAK-418.

Journal: EJNMMI research
Published: April 03, 2026

Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain.

Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain.

Journal: Journal of medicinal chemistry
Published: October 21, 2025

Development of 18F/11C-Labeled Pyrrolo-Pyridine/Pyrimidine LRRK2 Selective PET Radioligands.

Development of 18F/11C-Labeled Pyrrolo-Pyridine/Pyrimidine LRRK2 Selective PET Radioligands.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 01, 2025

Evaluation of [18F]MNI-1054, a novel PET ligand for lysine-specific histone demethylase 1A (LSD1), in non-human primates.

Evaluation of [18F]MNI-1054, a novel PET ligand for lysine-specific histone demethylase 1A (LSD1), in non-human primates.

Journal: EJNMMI research
Published: May 15, 2025

Radiosynthesis and Evaluation of 11C‑Labeled Imidazolyl Pyrimidine Derivatives for Positron Emission Tomography Imaging of Glycogen Synthase Kinase‑3.

Radiosynthesis and Evaluation of 11C‑Labeled Imidazolyl Pyrimidine Derivatives for Positron Emission Tomography Imaging of Glycogen Synthase Kinase‑3.

Journal: ACS pharmacology & translational science
Published: January 10, 2025

Radiolabeling and Preliminary In Vivo Evaluation of the Candidate CCR2 Targeting PET Radioligand [11C]AZD2423.

Radiolabeling and Preliminary In Vivo Evaluation of the Candidate CCR2 Targeting PET Radioligand [11C]AZD2423.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 06, 2024

Temporal progression of tau pathology and neuroinflammation in a rhesus monkey model of Alzheimer's disease.

Temporal progression of tau pathology and neuroinflammation in a rhesus monkey model of Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: January 17, 2024

Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [18F]FE-PE2I-OH for Translational Dopamine Transporter Imaging.

Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [18F]FE-PE2I-OH for Translational Dopamine Transporter Imaging.

Journal: ACS chemical neuroscience
Published: September 27, 2023

First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.

First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 10, 2022

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates.

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates.

Journal: EJNMMI research
Published: July 13, 2021

Multiple Applications of a Novel Biarsenical Imaging Probe in Fluorescence and PET Imaging of Melanoma.

Multiple Applications of a Novel Biarsenical Imaging Probe in Fluorescence and PET Imaging of Melanoma.

Journal: Bioconjugate chemistry
Published: February 12, 2021

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.

Journal: Journal of medicinal chemistry
Published: July 15, 2020
Showing 1-12 of 72

Last Updated: 09/26/2026